Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07354620 · ClinicalTrials.gov registry record · Early Phase 1
A Pilot Study on Reverse Aging (The REVERSE Study)
A Early Phase 1 study of Aging, sponsored by The Christ Hospital.
- Active
- Registry status
- Early Phase 1
- Development phase
- 52
- Enrollment target
- 1
- Study location
NCT07354620: Active Early Phase 1 study of Aging, sponsored by The Christ Hospital.
NCT07354620 is a Early Phase 1 study of Aging that is active but no longer recruiting, run by The Christ Hospital. The registered enrollment target is 52 participants, below the 2,194-participant average among 262 other Aging trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07354620, a Early Phase 1 study of Aging, is active but no longer recruiting, sponsored by The Christ Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 52 participants
- Enrollment target
- 1
- Study location
Study Summary
Aging can be defined as a time-dependent functional decline in physiological function, which may increase the vulnerability to diseases and eventually death. The question is whether aging is a normal process, or exists as an "uber-illness?" Work done by Dr Sinclair at Harvard suggests the latter. Dr. Sinclair feels people should be able to age-in-place, or even reverse age. Aging is arguably the single biggest risk factor for all acquired and chronic diseases. Delaying the aging rate by 7 years would cut the incidence of chronic disease in half! Up until know the effects of anti-aging would need longitudinal studies until death. Now, with the advent of a 3rd generation OMIC Age clock, there is a way to assess if an intervention is changing the rate of aging and other methylation patterns associated with aging.
Primary Outcome
To evaluate the gradated effects of mTOR inhibition on a new OMIC methylation test that evaluates biological (vs chronological) age over a six-month period.
Conditions Studied
Interventions
- DRUG Rapamycin (Tablets)
- DIETARY_SUPPLEMENT Prolon diet
Study Locations (1)
Ohio
- AIM for Wellbeing - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2025-02-15 |
| Est. Completion | 2026-05 |
| Phase | Early Phase 1 |
What the registry record for NCT07354620 still lists
NCT07354620 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 2,194-participant average among 262 other Aging trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Aging appearing as the primary indexed condition, and to 2 interventions - of which Rapamycin (Tablets) is the first listed.
NCT07354620 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT07354620 about?
NCT07354620 is a clinical study titled "A Pilot Study on Reverse Aging (The REVERSE Study)". Aging can be defined as a time-dependent functional decline in physiological function, which may increase the vulnerability to diseases and eventually death. The question is whether aging is a normal process, or exists as an "uber-illness?" Work done by Dr Sinclair at Harvard suggests the latter. Dr...
What is the current status of trial NCT07354620?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 52 participants. The study started on 2025-02-15. Estimated completion is 2026-05.
What conditions does trial NCT07354620 study?
This clinical trial studies the following conditions: Aging.
What interventions are being tested in trial NCT07354620?
The interventions under investigation include: Rapamycin (Tablets) (DRUG), Prolon diet (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07354620?
This trial is sponsored by The Christ Hospital, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07354620 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Aging
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07354620's enrollment target sits among peer trials
52 154th of 262 higher than 109 of 262 other Aging trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Aging trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Gene Expression Changes In Young and Geriatric Skin
RECRUITING · Early Phase 1
-
Examining the Effects of Theta Burst TMS on Brain Connectivity and Balance Ability in Older Adults With Balance Problems
RECRUITING · Early Phase 1
-
Transient Receptor Potential Channels
RECRUITING · Early Phase 1
-
Early Neurovascular Adaptations in Aging Women
RECRUITING · Early Phase 1
-
Heat, Microvascular Function and Aging
RECRUITING · Early Phase 1
-
Angiotensin-(1-7) Cardiovascular Effects in Aging
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI